Watch · Quality 22/100
Simple research view
VRTX · Vertex Pharmaceuticals Incorporated
$479.00 latest stored close
1 independent risk warning also present. Review before relying on the bullish setup.
Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.
$VRTX
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals Incorporated is a large-cap Pharmaceuticals: Major company in the Health Technology sector with a market cap of $122B.
⚠ Risk Signals
Head & Shoulders Top
Neckline ~479.16 has broken. Measured-move risk extends toward ~424.64; a fast reclaim of 479.16 would be a failed breakdown (often bullish).
Bearish structure on the daily chart — a heads-up for anyone holding, not a short signal. Does not affect the bullish setup score.
Council read · 6 methods
Watch — evidence is building
0 buyable · 5 watch · 1 avoid. Review the observed passes and blockers before reading the chart.
Earnings-risk mode
Pre-earnings setup
Monday, August 3, 2026
Time not confirmed
No sourced report session or clock time
Deterministic evidence
VRTX+0.34%
Sector proxy · XLV+0.51%
Broad market · SPY+0.02%
CatalystUnavailable
Stock reactionPositive
Sector reactionSupportive
Opening surgeUnavailable
Event riskEarnings-driven
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.
AI interpretation (optional)
Ask a Legend to interpret the evidence only after reviewing the deterministic event timing and relative reaction.
Interpret this evidence AI output is commentary, not scanner evidence or a sizing recommendation.VRTX Chart
Interactive price, volume, RS, RSI, and MACD charts are available after sign in.
Setup Quality
C
3/7 signals
Score trend
✓
Stage 2 · Advancing
✗
Power Trend
✗ RS New High
✓ Trend 7/8
✗
No Pattern
✗ CANSLIM 56.9 (C)
✓ Gatekeeper
Base #2 (B)
Technical Analysis Report Card
$VRTX · $479.00 · as of 2026-07-27 · multi-factor read
66
/ 100
Trend · Daily / Weekly / Monthly
Daily
▬ Sideways / consolidating
Weekly
▲ Uptrend
Monthly
▲ Uptrend
Moving Averages
50-day$464.82 ↑
100-day$455.24 ↑
200-day$451.53 ↑
Bullish (50 > 200)
RSI (14)
Reading50.1 · Neutral
Neutral — momentum is balanced between buyers and sellers.
MACD (12/26/9)
StateWeakening
Histogram-3.472
Weakening — MACD slipped below its signal line. Histogram expanding.
Bollinger Bands (20,2)
%B / Width33% · 14.3%
Mid-band — no directional band edge in play.
Volume · Buyer vs Seller
Up/Down vol0.99 · Neutral
Rel volume1.01×
Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.
Support & Resistance
R · $486.26swing level
R · $500.95swing level
R · $507.92swing level
Price · $479.00now
S · $469.60swing level
S · $452.53swing level
S · $443.12swing level
Fibonacci · Uptrend swing
23.6%$505.02
38.2%$487.30
50.0% ◄ price here$472.97
61.8%$458.64
78.6%$438.25
Retracement support zones measured from the recent swing low up to the high.
The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for VRTX — plus the full 495-symbol scanner and Ask-the-Legends chat.
🔒 Start your 7-day free trial →
Weekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishRS 23 (laggard)
Want this read in a legend's voice?
💬 Ask a Legend about VRTX
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts
6 methodology checks
Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
Council consensus:
🟡 5 of 6 legends are Watching — building, not yet a confirmed buy.
Watch
Minervini C
Trend-template read: 9/13 pass; wait for the soft misses to improve.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $479.00, MA150 $459.10, MA200 $451.53
1.2 150-day MA > 200-day MAMA150 $459.10 vs MA200 $451.53
Failing evidence
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 23
2. Quarterly EPS growth ≥ 25%-11.1% QoQ
Avoid
O'Neil D
CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
A: Annual earnings & revenue qualityRev +8.9% | ROE 23.9%
N: Near 52-week high or RS line new high10.2% below high | RS line new high: False
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-11.1% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 23
Watch
Weinstein C
Stage-analysis read: Stage 2 is present; 3 supporting checks need improvement.
Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $479.00 vs MA200 $451.53
Failing evidence
Volume expansion above averageVolume ratio 1.01x
Relative strength ≥ 60RS 23
Watch
Livermore B
Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$479.00
Distance from 52-week high10.2% below high
Failing evidence
Relative strengthRS 23
Volume vs average1.01x
Watch
Darvas B
Box-theory read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$479.00
Distance from 52-week high10.2% below high
Failing evidence
Relative strengthRS 23
Volume vs average1.01x
Watch
Wyckoff B
Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$479.00
Distance from 52-week high10.2% below high
Failing evidence
Relative strengthRS 23
Volume vs average1.01x
Breakout Health
No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?
🕯 Latest candle: Shooting Star — Long upper shadow with a small body near the low — sellers rejected higher prices. A caution flag when price is extended above a pivot.
RS Line vs SPY
52-week relative strength · blue = RS line · dashed = MA50 · dot = NH
▼ Falling
Accumulation / Distribution
last 65 sessions · green = acc on high vol · red = dist on high vol
Net +8
Fundamentals & leadership quality — Minervini SEPA criteria · 4/7 met
B
4/7 SEPA
Separate score from the 8-point Trend Template (7/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
EPS acceleration ≥25% QoQ
-11%
Revenue growth ≥20% YoY
+9%
Gross margin ≥30%
86%
ROE ≥17%
24%
RS rating ≥80 (leadership)
23
Stage 2 uptrend (Weinstein)
Stage 2
Within 25% of 52W high
-10.2%
Method Playbook
📋 Trade it like Wyckoff
EXACT LEVELS · PRO
Wyckoff B · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro levelPublished-method rule: Use the Spring/test, Sign of Strength, creek, or Last Point of Support boundary identified by the active structure.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro levelPublished-method rule: Require a completed test or Sign of Strength/Last Point of Support confirmation with improving demand versus supply.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro levelPublished-method rule: Start below the Spring/test low or structural support whose failure would invalidate the accumulation read.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-basedPublished-method rule: Raise protection beneath successive Last Points of Support or meaningful higher lows during markup; never loosen it.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro levelPublished-method rule: Exit on a failed Sign of Strength, support loss, or clear supply-dominant reversal such as an upthrust failure.
Evidence: Canonical setup geometry is available with Pro.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →
The published-method workflow is public. Unlock exact pivot, entry, stop, target, and sizing with Pro →
Pattern Analysis
Wyckoff SOS
⚠ Head & shoulders top (neckline confirmed)
50.0
score
RS Score
23
Trend
7/8 ✓
CANSLIM
56.9* (C)
range low: 427.065
range high: 483.841
range pct: 0.133
sos thrust: 0.015
sos vol ratio: 6.423
sos bars ago: 20
near lps: ✓
validation reason: valid generic setup
multi tf evaluated: ✓
multi tf reason: weekly: MA stabilizing or rising — accumulation context supported
Why This Setup?
Wyckoff SOS
SOS: breakout above range_high=483.84, thrust=1.5%, vol=6.4x avg, lps=near, 20 bars ago | Strong trend (7/8) | High-confidence pattern (85%) | Stage 2 | Readiness 73/100 (watch) | CANSLIM 56.9 (C) | ⚠ Head & shoulders top (neckline confirmed)
The Universal Edge Check
The panel is uneasy
Too many universals unmet — this leans closer to a guess than a trade.
1/7
universals met
- In a confirmed uptrend Stage 2 · Trend 7/8
- Risk is defined No stop — undefined risk
- Asymmetric reward No target set
- Not chasing (in range) Pivot distance unknown
- Volume confirms 1.0× average — light
- Clear of earnings in 6 days — event risk
- A relative-strength leader RS 24 — laggard
Minervini Trend Template
7/8Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.
Price above SMA 150 & 200
$479.00 vs SMA150 $459.10 / SMA200 $451.53
SMA 150 above SMA 200
SMA150 $459.10 vs SMA200 $451.53
SMA 200 trending up
Slope +9.89 over 20 days
SMA 50 above SMA 150 & 200
SMA50 $464.82
Price above SMA 50
$479.00 vs SMA50 $464.82
30%+ above 52W low
+32.1% from $362.50
Within 25% of 52W high
-10.2% from $533.67
RS score above 70
RS 23
Fundamentals
52W Range
68%
Mkt Cap SEC
121.6B
EPS QoQ
-11%
Rev YoY
+9%
ROE
24%
Gross Margin
86%
D/E
0.01
EPS TTM
$15.32
P/E TTM
31.3x
Float
254M
Insider
No Buy
Company
Legend AI snapshot
Vertex Pharmaceuticals Incorporated
$479.00latest close
$121.6Bmarket cap
24RS rank
50setup score
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
C
56.9* CANSLIM
* disqualified on C, M
C · Curr. EPS
38
A · Annual EPS
77
N · New Highs
40
S · Supply/Demand
80
L · Leader RS
23
I · Inst. Spons.
100
M · Market
30
Weekly Context
Multi-timeframe signals from weekly barsW. Trend
7/8
W. RS
61
W. Support
$412.27
W. Resist
$533.67
Weekly Structure
Trend
Neutral
Tight Weeks
0
Confirmation
Neutral
Scan History
20× streakJul 28
Wyckoff SOS
✓ Gate
68
Jul 28
Wyckoff SOS
✓ Gate
68
Jul 28
Wyckoff SOS
✓ Gate
50
Jul 27
Trend Only
✓ Gate
60
0.0%
Jul 27
Trend Only
✓ Gate
59
0.0%
Jul 24
Wyckoff SOS
✓ Gate
55
+0.3%
Get the full picture on VRTX
Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 495+ symbols daily.
Start 7-Day Free Trial